Targeting selective activation of M1 for the treatment of Alzheimers disease: Further chemical optimization and pharmacological characterization of the M1 positive allosteric modulator ML169

ACS Chemical Neuroscience

Volumn 3, Issue 11, 2012, Pages 884-895

  Tarr, James C ^a,b   Turlington, Mark L ^a,b   Reid, Paul R ^a,c   Utley, Thomas J ^a,b   Sheffler, Douglas J ^a   Cho, Hyekyung P ^a,b   Klar, Rebecca ^a   Pancani, Tristano ^a   Klein, Michael T ^a,b   Bridges, Thomas M ^a,b   Morrison, Ryan D ^a,b   Blobaum, Anna L ^a   Xiang, Zixui ^a   Daniels, J Scott ^a,b   Niswender, Colleen M ^a,b   Conn, P Jeffrey ^a,b   Wood, Michael R ^a,b   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c U S ARMY RESEARCH OFFICE   (United States)

Author keywords

acetylcholine; Alzheimers disease (AD); medium spiny neurons (MSNs); ML169; MLPCN; Muscarinic; positive allosteric modulator (PAM)

Indexed keywords

BETA SECRETASE 1; CARBACHOL; LEAD; ML 169; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MYOTONIC DYSTROPHY PROTEIN KINASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; MOUSE; NONHUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ALZHEIMER DISEASE; ANIMALS; COGNITION; DRUG DISCOVERY; INDOLES; MUSCARINIC AGONISTS; NEURONS; PROTEIN-SERINE-THREONINE KINASES; RATS; RECEPTOR, MUSCARINIC M1; SULFONES;

EID: 84869843357     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn300068s     Document Type: Article

References (42)

1. Langmead, C. J., Watson, J., and Reavill, C. (2008) Muscarinic acetylcholine receptors as CNS drug targets Pharmacol. Ther. 117, 232-243
2. Digby, G. J., Shirey, J. K., and Conn, P. J. (2010) Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders Mol. Biosyst. 6, 1345-1354
3. Caulfield, M. P. (1993) Muscarinic receptors - characterization coupling and function Pharmacol. Ther. 58, 319-379
4. Levey, A. I., Kitt, C. A., Simonds, W. F., Price, D. L., and Brann, M. R. (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies J. Neurosci. 11, 3218-3226
5. Levey, A. I., Edmunds, S. M., Koliatsos, V., Wiley, R. G., and Heilman, C. J. (1995) Expression of M1-M4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervations J. Neurosci. 15, 4077-4092
6. Levey, A. I. (1996) Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 93, 13541-13546
7. Felder, C. C., Porter, A. C., Skillman, T. L., Zhang, L., Bymaster, F. P., Nathanson, N. M., Hamilton, S. E., Gomeza, J., Wess, J., and McKinzie, D. L. (2001) Elucidating the role of muscarinic receptors in psychosis Life Sci. 68, 2605-2613
8. Anagnostaras, S. G., Murphy, G. G., Hamilton, S. E., Mitchell, S. L., Rahnama, N. P., Nathanson, N. M., and Silva, A. J. (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor in mutant mice Nat. Neurosci. 6, 51-58
9. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., Hurley, D. J., Potter, W. Z., and Paul, S. M. (1997) Effects of xanomeline, a selective muscarinic receptor agonsist, on cognitive and behavioral symptoms in Alzheimer disease Arch. Neurol. 54, 465-473
10. Caccamo, A., Oddo, S., Billings, L. M., Green, K. N., Martinez-Coria, H., Fisher, A., and LaFerla, F. M. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice Neuron 49, 671-682
11. Caccamo, A., Fisher, A., and LaFerla, F. M. (2009) M1 agonists as a potential disease-modifying therapy for Alzheimers disease Curr. Alzheimer Res. 6, 112-117
12. Jones, C. K., Brady, A. E., Davis, A. A., Xiang, Z., Bubser, M., Tantawy, M. N., Kane, A. S., Bridges, T. M., Kennedy, J. P., Bradley, S. R., Peterson, T. E., Ansari, M. S., Baldwin, R. M., Kessler, R. M., Deutch, A. Y., Lah, J. J., Levey, A. I., Lindsley, C. W., and Conn, P. J. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 28, 10422-10433
13. Shirey, J. K., Brady, A. E., Jones, P. J., Davis, A. A., Bridges, T. M., Jadhav, S. B., Menon, U., Christain, E. P., Doherty, J. J., Quirk, M. C., Snyder, D. H., Levey, A. I., Watson, M. L., Nicholle, M. M., Lindsley, C. W., and Conn, P. J. (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J. Neurosci. 29, 14271-14286
14. 1 receptor function ACS Chem. Neurosci. 1, 104-121
15. 1 muscarinic acetylcholine receptor induce brain region specific responses and correspond with behavioral effects in animal models J. Neurosci. 32, 8532-8544
16. Jian, S., Wang, Y., Ma, Q., Zhou, A., and Zhang, Y. W. (2012) M1 muscarinic acetylcholine receptor interacts with BACE1 and regulates its proteosomal degradation Neurosci. Lett. 515, 125-130
17. Zuchner, T., Perez-Polo, J. R., and Schliebs, R. (2004) Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling J. Neurosci. Res. 77, 250-257
18. Lindsley, C. W., Shipe, W. D., Wolkenberg, S. E., Theberge, C. R., Williams, D. L., Jr., Sur, C., and Kinney, G. G. (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia Curr. Topics Med. Chem. 8, 771-784
19. Conn, P. J., Tamminga, C., Schoepp, D. D., and Lindsley, C. W. (2008) Schizophrenia: moving beyond monoamine antagonists Mol. Interventions 8, 99-105
20. Bridges, T. M., LeBois, E. P., Hopkins, C. R., Wood, M. R., Jones, J. K., Conn, P. J., and Lindsley, C. W. (2010) Antipsychotic potential of muscarinic allosteric modulation Drug News Perspect. 23, 229-240
21. Sur, C., Mallogora, P. J., Wittman, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., and Conn, P. J. (2003) N -desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N -methyl-D-aspartate activity Proc. Natl. Acad. Sci. U.S.A. 100, 13674-13679
22. Bymaster, F. P., Whitesitt, C. A., Channon, H. E., DeLapp, N., Ward, J. S., Calligaro, D. O., Shipley, L. A., Buelke-Sam, J. L., Bodick, N. C., Farde, L., Sheardown, M. J., Olesen, P. H., Hansen, K. T., Suzdak, P. D., Swedberg, M. D. B., Sauerberg, P., and Mitch, C. H. (1997) Xanomeline: a selective muscarinic agonist for the treatment of Alzheimers disease Drug Dev. Res. 40, 158-170
23. Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dube, S., Mallinckrodt, C., Bymaster, F. P., McKinzie, D. L., and Felder, C. C. (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment for schizophrenia Am. J. Psychiatry 165, 1033-1039
24. Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., and Lindsley, C. W. (2012) Allosteric modulation of 7 transmembrane spanning receptors: theory, practice and opportunities for CNS drug discovery J. Med. Chem. 55, 1445-1464
25. Conn, P. J., Christopolous, A., and Lindsley, C. W. (2009) Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders Nat. Rev. Drug Discovery 8, 41-54
26. Kuduk, S. D., Chang, R. K., Di Marco, C. N., Ray, W. J., Ma, L., Wittmann, M., Seager, M. A., Koeplinger, K. A., Thompson, C. D., Hartman, G. D., and Bilodeau, M. T. (2010) Quinolizidinone carboxylic acids as CNS penetrant, selective M1 allosteric muscarinic receptor modulators ACS Med. Chem. Lett. 1, 263-267
27. Brady, A. E., Jones, C. K., Bridges, T. M., Kennedy, J. P., Thompson, A. D., Heimann, J. U., Breininger, M. L., Gentry, P. R., Yin, H., Jadhav, S. B., Shirey, J. K., Conn, P. J., and Lindsley, C. W. (2008) Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats J. Pharmacol. Exp. Ther. 327, 941-953
28. Bridges, T. M., Kennedy, J. P., Hopkins, C. R., Conn, P. J., and Lindsley, C. W. (2010) Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators Bioorg. Med. Chem. Lett. 20, 5617-5622
29. Ma, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., McCampbell, A., Gaspar, R., Shughrue, P., Danziger, A., Regan, C., Flick, R., Pascarella, D., Garson, S., Doran, S., Kreatsoulas, C., Veng, L., Lindsley, C. W., Shipe, W., Kuduk, S., Sur, C., Kinney, G., Seabrook, G. R., and Ray, W. J. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 106, 15950-15955
30. Bridges, T. M., Kennedy, J. P., Noetzel, M. J., Breininger, M. L., Gentry, P. R., Conn, P. J., and Lindsley, C. W. (2010) Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAM Bioorg. Med. Chem. Lett. 20, 1972-1975
31. Reid, P. R., Bridges, T. M., Sheffler, D. J., Cho, H. P., Lewis, L. M., Days, E., Daniels, J. S., Jones, C. K., Niswender, C. M., Weaver, D. C., Conn, P. J., Lindsley, C. W., and Wood, M. R. (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, and MLPCN probe Bioorg. Med. Chem. Lett. 21, 2697-2701
32. 1 positive allosteric modulators Bioorg. Med. Chem. Lett. 20, 531-536
33. Billingsley, K. and Buchwald, S. L. (2007) Highly efficient monophosphine-based catalyst for the palladium-catalyzed Suzuki-Miyaura reaction of heteroaryl halides and heteroaryl boronic acids and esters J. Am. Chem. Soc. 129, 3358-3366
34. Xiang, Z., Thompson, A. D., Jones, C. K., Lindsley, C. W., and Conn, P. J. (2012) Roles of the m1 muscarinic acetylcholine receptor subtype in the regulation of Basal Ganglia function and implications for the treatment of Parkinsons disease J. Pharmacol. Exp. Ther. 340, 595-603
35. Shen, W., Tian, X., Day, M., Ulrich, S., Tkatch, T., Nathanson, N. M., and Surmeier, D. J. (2007) Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons Nat. Neurosci. 10, 1458-1466
36. Graybiel, A. M., Aosaki, T., Flaherty, A. W., and Kimura, M. (1994) The basal ganglia and adaptive motor control Science 265, 1826-1831
37. Nicola, S. M., Surmeier, J., and Malenka, R. C. (2000) Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens Annu. Rev. Neurosci. 23, 185-215
38. Holt, D. J., Herman, M. M., Hyde, T. M., Kleinman, J. E., Sinton, C. M., German, D. C., Hersh, L. B., Graybiel, A. M., and Saper, C. B. (1999) Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia Neuroscience 94, 21-31
39. Lehericy, S., Hirsch, E. C., Cervera, P., Hersh, L. B., Hauw, J. J., Ruberg, M., and Agid, Y. (1989) Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 86, 8580-8584
40. Pisani, A., Bernardi, G., Ding, J., and Surmeier, D. J. (2007) Re-emergence of striatal cholinergic interneurons in movement disorders Trends. Neurosci. 30, 545-553
41. Simpson, E. H., Kellendonk, C., and Kandel, E. (2010) A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia Neuron 65, 585-596
42. Fisher, A. (2008) Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimers disease Neurotherapeutics 5, 433-442